Arcutis Strategy and Business Model

Executive Overview

Arcutis is a U.S.-based biopharmaceutical company focused on medical dermatology. Founded in 2016 and headquartered in Westlake Village, California, the company has built its strategy around topical roflumilast, a phosphodiesterase-4 (PDE4) inhibitor formulated for chronic inflammatory skin diseases. Its commercial franchise is branded as Zoryve, with approved products in plaque psoriasis and seborrheic dermatitis as of mid-2024, and an additional atopic dermatitis application under U.S. Food and Drug Administration review at that time. Arcutis operates in a large but highly competitive market where physicians and patients want steroid-sparing options that combine strong efficacy, tolerability, and ease of use.

Strategically, Arcutis is trying to do more than launch a single drug. It is building a focused dermatology company around a multi-indication franchise, using formulation fit, label expansion, and specialist commercialization to increase the value of one core molecule across several common skin conditions. That makes the company different from a broad pharmaceutical company and also different from a single-asset development-stage biotech. For FY2024, revenue was #N/A. As of 2024, Arcutis remained primarily U.S.-focused commercially, with the key near-term question being how effectively it could convert clinical differentiation into durable prescription growth, payer access, and operating leverage.

Arcutis at a Glance

Logo
Common name	Arcutis
Full legal name	Arcutis Biotherapeutics, Inc.
Headquarters	Westlake Village, California, USA
Ownership	Public company; no controlling shareholder disclosed in 2024 proxy materials
Ticker	ARQT
Exchange	NASDAQ
Market Cap	$3.28B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2016; Nasdaq IPO in 2020; first FDA approval for Zoryve cream 0.3% in plaque psoriasis in 2022; FDA approval for Zoryve foam 0.3% in seborrheic dermatitis in 2023
Industry or industries	Biopharmaceuticals; medical dermatology; immuno-dermatology
Key products or services	Zoryve prescription dermatology therapies based on topical roflumilast; dermatology drug development and commercialization
Geographic footprint	Primarily United States commercial footprint as of 2024, with selective international partnering rather than a broad owned ex-U.S. infrastructure
Business segments as officially reported	One reportable segment
Company website	https://www.arcutis.com/

1. What Is the Strategy of Arcutis?

Arcutis has described itself as a medical dermatology company built to address major unmet needs in common inflammatory skin diseases. Using the Playing to Win framework, its strategy is best understood as a focused effort to build a multi-indication dermatology franchise around one clinically differentiated molecule and then scale a specialist commercial platform around it.

1. 1a. What is the winning aspiration of Arcutis?

   Arcutis’s public messaging has centered on becoming a leading medical dermatology company and improving the standard of care in high-prevalence inflammatory skin diseases. In practical terms, “winning” means turning topical roflumilast into a durable franchise across multiple common indications rather than being a one-product niche company. As of mid-2024, management’s emphasis was less on long-range public margin targets and more on commercial traction, indication expansion, and establishing Zoryve as a broadly recognized non-steroidal prescription option.

2. 1b. Where does Arcutis play?

   Arcutis plays in prescription medical dermatology, especially chronic inflammatory skin conditions treated largely in outpatient settings. Its initial focus has been on plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, with an emphasis on patients and prescribers seeking steroid-sparing topicals. Geographically, the company has been primarily U.S.-focused commercially as of 2024. Channel-wise, it plays through dermatology prescribers, pharmacies, payers, and patient-support infrastructure rather than through broad primary-care mass promotion.

3. 1c. How does Arcutis plan to win?

   Arcutis aims to win through product differentiation and focus. The core value proposition is a non-steroidal topical therapy with a combination of efficacy, tolerability, once-daily dosing, and formulation suitability for difficult treatment areas. The company is also trying to win by reusing the same molecule across multiple indications and dosage forms, which can improve brand efficiency, physician familiarity, and commercial returns. A second element is specialist execution: strong dermatology field promotion, payer access work, and medical affairs support are all necessary to translate clinical data into prescriptions.

4. 1d. What capabilities must Arcutis have in place?

   To execute this strategy, Arcutis needs several capabilities that are unusually important for a focused dermatology biotech. These include formulation science; clinical development in dermatology; regulatory execution for supplemental indications; market-access management; specialty-commercial infrastructure; medical affairs and key-opinion-leader engagement; and reliable technical operations through third-party manufacturing. Because the company is trying to create a franchise rather than just win a single approval, it also needs disciplined lifecycle-management capability.

5. 1e. What management systems does Arcutis require?

   Arcutis needs management systems that are prescription-data driven and tightly cross-functional. Key systems include launch dashboards, gross-to-net pricing controls, formulary and prior-authorization tracking, pharmacovigilance and quality systems, sales-force targeting, and portfolio-allocation routines that rank development programs by probability of approval and commercial value. For a company at Arcutis’s stage as of 2024, execution discipline matters as much as scientific success: management has to balance R&D investment, launch spending, inventory build, and cash runway at the same time.

2. What Are the Current Strategic Initiatives of Arcutis?

As of 2024, Arcutis’s public strategic agenda was concrete and commercially oriented. The company was no longer just proving science; it was building a franchise.

Scale Zoryve in approved indications

Arcutis’s first major initiative has been driving prescription growth for approved Zoryve products. That means increasing physician awareness, improving payer coverage, reducing patient access friction, and building repeat use in chronic conditions where refill behavior matters. Commercial execution in plaque psoriasis and seborrheic dermatitis has been central.

Expand the label into atopic dermatitis

A second major initiative has been supplemental regulatory expansion. As of mid-2024, Arcutis had an application under FDA review for Zoryve cream 0.15% in atopic dermatitis. This matters strategically because atopic dermatitis is a large market and because success would broaden the Zoryve franchise beyond psoriasis and seborrheic dermatitis.

Build a franchise brand across formulations

Arcutis has been pursuing a franchise model rather than a single-formulation model. The approval of Zoryve foam 0.3% for seborrheic dermatitis in late 2023 reinforced that approach. Different skin conditions and body sites require different vehicles, and formulation fit can influence both physician adoption and patient adherence.

Improve access economics

For branded dermatology products, gross prescription demand is not enough. Arcutis has needed to improve payer access, affordability support, and prescription conversion. This is an operating initiative as much as a commercial one, because abandonment at the pharmacy counter can materially affect growth.

Manage cash while investing behind launches

Arcutis has also had to manage the classic commercial-stage biotech transition: spend aggressively enough to build a franchise, but selectively enough to preserve financial flexibility. Public disclosures in 2024 suggested a continued focus on prioritizing the highest-value commercial and development opportunities rather than broad, unfocused expansion.

3. What Is the Business Model of Arcutis?

Arcutis uses a branded prescription-biopharma model focused on dermatology.

• What customers actually buy. The immediate economic transaction is a sale of branded prescription product into the pharmaceutical channel, typically through wholesalers or distribution partners, with dispensing through retail or specialty pharmacies. The ultimate demand, however, comes from physicians who prescribe and patients who fill and refill the prescription.
• Recurring versus one-time revenue. The model is primarily repeat-driven rather than one-time. Psoriasis, seborrheic dermatitis, and atopic dermatitis are chronic or recurrent conditions, so successful prescriptions can lead to refill behavior and multi-year patient value. That said, persistence varies by indication, severity, payer access, and patient experience.
• How pricing power works. Arcutis has some list-price discretion as a branded innovator, but real pricing power is constrained by pharmacy benefit managers, rebates, copay support, Medicaid discounts, and competitive alternatives. Net realized price matters more than headline wholesale acquisition cost.
• Why the business mix matters. Product revenue is strategically more valuable than one-time collaboration or milestone revenue because it can compound with prescription growth. Expanding Zoryve into new indications also improves sales-force productivity because one commercial platform can support multiple products and messages.
• What drives gross margin. For a topical branded pharmaceutical product, manufacturing cost of goods is usually modest relative to net sales once scale is achieved, so gross margin can become attractive. The larger issue is not usually gross margin but the gross-to-net deduction structure.
• What drives operating margin and cash generation. Operating margin depends heavily on commercial spend, R&D expense, and launch timing. Cash generation improves when prescription growth starts to outpace selling and development spend, but as of 2024 Arcutis was still in a scale-building phase rather than a mature cash-harvesting phase.
• Revenue model. The core model is branded prescription revenue. It is not subscription-based or transaction-fee based. In substance, it is a repeat-prescription annuity model built on clinical differentiation, payer access, and adherence.

4. What Products and/or Services Does Arcutis Sell?

Arcutis’s commercial and strategic focus is concentrated. As of mid-2024, the company’s most important offerings were all part of the Zoryve franchise.

Zoryve cream 0.3%

Zoryve cream 0.3% was approved by the FDA in 2022 for plaque psoriasis. This product established Arcutis as a commercial company and gave it an entry point into prescription dermatology. Its strategic importance goes beyond the initial indication because it validated the molecule, the formulation approach, and the company’s commercial build-out.

Zoryve foam 0.3%

Zoryve foam 0.3% was approved by the FDA in late 2023 for seborrheic dermatitis. The foam matters because vehicle choice is important in dermatology, especially for hair-bearing areas such as the scalp. This launch broadened the Zoryve franchise and showed how Arcutis intends to match formulation to disease presentation.

Zoryve cream 0.15% for atopic dermatitis

As of mid-2024, Zoryve cream 0.15% for atopic dermatitis was under FDA review and had not yet been approved. Publicly, this was one of the company’s most important near-term value drivers because atopic dermatitis is a large and commercially significant market.

Development-stage dermatology programs

Arcutis has also invested in broader immuno-dermatology development programs, but by 2024 the overwhelming center of gravity was the roflumilast-based Zoryve franchise. In strategic terms, Arcutis was prioritizing programs that could either expand the core brand or reinforce its position in medical dermatology rather than building a highly diversified pipeline for its own sake.

5. What Are the Key Competitors or Peers of Arcutis?

Arcutis’s competitive set depends on the indication. Some rivals are direct topical competitors, while others are substitutes used in more severe disease or different lines of therapy.

In addition to these named companies, low-cost generic topical corticosteroids, calcineurin inhibitors, and antifungal therapies remain important substitutes. In day-to-day practice, Arcutis is often competing not only against another branded product, but also against physician habit, formulary restrictions, and the low upfront cost of older generics.

6. What Is the Marketing Strategy of Arcutis?

Arcutis’s marketing strategy is consistent with a specialty pharmaceutical company rather than a mass-market consumer health company. The primary objective is to change prescribing behavior among dermatology-focused clinicians and then make it easy for patients to obtain and stay on therapy.

The most important elements appear to be:

• Targeted prescriber promotion. Arcutis markets mainly to dermatologists and other relevant specialists, using clinical data, product differentiation, and disease-state education.
• Medical affairs support. In prescription dermatology, peer-to-peer education, congress presence, and key-opinion-leader engagement matter. Marketing is reinforced by scientific credibility.
• Access and affordability messaging. For a branded product, demand generation is incomplete without payer support, copay assistance, and clear fulfillment pathways.
• Franchise brand building. Zoryve is being developed as a franchise brand across formulations and indications. That gives Arcutis some brand leverage, although clinical profile and reimbursement still matter more than consumer-style brand advertising.

Based on the company’s business model, marketing is an important enabling capability rather than the sole differentiator. Arcutis still needs physicians to believe the product is clinically compelling and payers to make access workable. Marketing succeeds when it shortens the path from clinical interest to filled prescription.

7. What Are the Key Customer Segments of Arcutis?

Arcutis serves several overlapping customer groups, and understanding the distinction matters.

• Dermatologists and advanced practice clinicians. These are the most important prescribers. They decide whether Zoryve enters the treatment algorithm and for which patient profiles.
• Pediatric dermatologists and selected pediatric prescribers. This segment matters as the company pursues indications that include younger patients, such as seborrheic dermatitis and atopic dermatitis.
• Patients with chronic inflammatory skin disease. End patients are central because adherence, satisfaction, tolerability, and ease of use shape refill behavior and physician confidence.
• Payers and pharmacy benefit managers. These are not end users, but they are crucial economic gatekeepers. Formulary placement and prior-authorization burden can materially affect uptake.
• Pharmacies, specialty pharmacies, and distributors. These are channel customers that help convert prescriptions into dispensed product.

Arcutis is focused rather than broadly diversified. Its end markets are all within medical dermatology, but they are diversified across multiple high-prevalence inflammatory conditions. That gives the company some portfolio breadth without diluting its commercial specialization.

8. What Is the Sales Model of Arcutis?

Arcutis uses a specialty-pharma sales model built around focused field promotion and pharmacy-channel fulfillment.

In practical terms, the company generates demand through a targeted commercial organization calling on high-value prescribers, while product reaches patients through third-party pharmaceutical distribution and dispensing channels. The company also needs account-management capabilities for payers and organized customers, and support functions that help patients navigate affordability and access.

This channel structure affects performance in several ways:

• Growth. Prescription growth depends on both new prescribers and the conversion of written prescriptions into dispensed scripts.
• Pricing. Net pricing is shaped by payer contracts, rebates, and patient-support economics, not just by the list price.
• Customer intimacy. Arcutis’s most important relationships are with a relatively concentrated set of dermatology prescribers and key accounts rather than millions of anonymous consumers.
• Execution risk. Delays in coverage, prior authorization, or pharmacy processing can slow growth even when physician demand is strong.

For Arcutis, the sales model is therefore tightly linked to commercialization analytics, territory design, hub performance, and gross-to-net discipline.

9. In What Geographies Does Arcutis Operate?

As of 2024, Arcutis was primarily a U.S.-focused company. Its headquarters are in Westlake Village, California, and its commercial effort has been built mainly around the U.S. prescription dermatology market.

The company’s customer base, product launches, and regulatory milestones have been centered on the United States. That does not mean all activity is physically domestic. Like many biopharmaceutical companies, Arcutis likely relies on a network of external partners for manufacturing, testing, clinical trial execution, and logistics that can span multiple countries. But commercially, the business has been concentrated rather than globally diversified.

This geographic profile matters strategically. It keeps the operating model focused and avoids the cost of building large ex-U.S. commercial infrastructure too early. At the same time, it leaves open a future growth path through partnerships, licenses, or selective international expansion if the Zoryve franchise continues to broaden.

10. Who Are the Owners of Arcutis?

Arcutis is a publicly traded company listed on Nasdaq under the ticker ARQT. As of the company’s 2024 proxy materials, no controlling shareholder was disclosed.

Ownership has been primarily institutional, which is typical for a small-cap biotech. Public filings in 2024 showed large asset managers such as The Vanguard Group and BlackRock among notable holders, while specialist healthcare investors have also been important shareholders at times. Exact percentages are time-sensitive and can change materially with financings, market moves, or fund rebalancing.

11. How Is Arcutis Organized?

Officially, Arcutis has reported one operating segment. Practically, however, it is organized like a focused commercial-stage biotech with several functional pillars:

• Research and development. Clinical development, translational work, formulation science, and regulatory planning.
• Medical affairs and pharmacovigilance. Scientific exchange, safety monitoring, and evidence support.
• Commercial. Sales, marketing, market access, patient services, and account management.
• Technical operations. Manufacturing oversight, quality, supply planning, and external partner management.
• General and administrative. Finance, legal, compliance, human resources, and corporate functions.

The company is not a diversified holding company and does not have a large multi-division brand portfolio. Its structure reflects concentration around one main franchise and the need to coordinate closely across R&D, regulatory, access, and commercial execution.

12. How Does Arcutis Operate?

On a day-to-day basis, Arcutis operates as a dermatology-focused pharmaceutical company that integrates development, regulatory execution, outsourced supply, and specialist commercialization.

1. Develop and refine formulations. The company conducts formulation and clinical work aimed at matching the product vehicle to the disease setting and treatment site.
2. Run clinical and regulatory programs. It designs and executes trials, compiles regulatory submissions, and manages interactions with the FDA.
3. Oversee external manufacturing. Arcutis relies on third-party manufacturers and related partners for production, quality release activities, and packaging, while retaining oversight responsibilities.
4. Create demand through a focused field force. Commercial teams call on dermatology prescribers, supported by marketing and medical affairs.
5. Manage access and dispensing. The company works through pharmacies and reimbursement pathways to convert prescriptions into filled scripts.
6. Track refill behavior and launch performance. Because the business depends on repeat prescriptions, data on abandonment, access friction, and persistence are operationally important.

The main operational bottlenecks are typical of branded dermatology: payer restrictions, prescription abandonment, launch inventory planning, and the need to synchronize regulatory timing with commercial readiness. For Arcutis, operational excellence is not about running factories at scale; it is about coordinating a complex externalized pharmaceutical value chain while building a highly effective commercial machine.

13. What Are the Growth Opportunities for Arcutis?

Arcutis has several plausible growth vectors, most of them tied to expanding and deepening the Zoryve franchise.

• Atopic dermatitis expansion. The most obvious near-term opportunity as of mid-2024 was approval and launch in atopic dermatitis, a large market with significant demand for non-steroidal options.
• Greater penetration in approved indications. Even without new labels, Arcutis can grow by improving physician awareness, payer access, and refill dynamics in plaque psoriasis and seborrheic dermatitis.
• Franchise productivity across formulations. More approved formulations and use settings can increase the productivity of the same sales force and the same prescriber relationships.
• Pediatric and line-extension opportunities. Dermatology markets can expand meaningfully when labels broaden across age groups or treatment sites, assuming data support those moves.
• Selective international partnering. Arcutis remains primarily U.S.-based commercially, so ex-U.S. partnering could add growth without requiring a full overseas sales build-out.
• Additional immuno-dermatology assets. Over time, the company could broaden beyond roflumilast if it identifies assets that fit the same commercial channel and physician base.

The main constraints are also clear: payer access can slow adoption; large pharma and specialty dermatology competitors are active; and Arcutis still has to balance growth investment with financial discipline. For a company at this stage, execution risk is as important as market size.

14. What Is the History of Arcutis?

Arcutis was founded in 2016 by biotech veterans focused on building a medical dermatology company. From the start, the company’s identity was tied to a relatively narrow but potentially valuable strategic idea: use strong science and thoughtful formulation work to address common inflammatory skin diseases that often remain frustrating for patients and physicians.

The company went public on Nasdaq in 2020, giving it access to capital needed for late-stage development and commercialization. A major turning point came in 2022, when the FDA approved Zoryve cream 0.3% for plaque psoriasis. That moved Arcutis from a development-stage biotech toward a commercial-stage company.

Another important milestone came in late 2023, when the FDA approved Zoryve foam 0.3% for seborrheic dermatitis. By mid-2024, the next major historical step underway was the FDA review of Zoryve cream 0.15% for atopic dermatitis. In short, Arcutis’s history has been less about acquisitions or portfolio reshuffling and more about steadily converting one dermatology platform into a broader commercial franchise.

15. What Are the Key Brands Owned by Arcutis?

Arcutis’s key brand is Zoryve. Unlike a diversified consumer-health company, Arcutis does not rely on a large stable of standalone brands. Its brand strategy is concentrated around building Zoryve into a recognizable prescription franchise across indications and formulations.

• Zoryve cream. The cream format anchors the psoriasis franchise and, as of mid-2024, was also central to the company’s atopic dermatitis expansion effort.
• Zoryve foam. The foam format extends the brand into use cases where a foam vehicle is more practical, especially seborrheic dermatitis involving the scalp and other hair-bearing areas.

Branding matters, but not in the same way it would for consumer packaged goods. In Arcutis’s case, the brand is valuable because it can reduce physician learning costs, improve franchise coherence, and support sales-force efficiency across multiple indications. Clinical profile and reimbursement, however, remain more important than brand imagery alone.

16. How Does the Supply Chain of Arcutis Function?

Arcutis’s supply chain is important, but it is not built around owned manufacturing scale. Like many biopharmaceutical companies, Arcutis has disclosed reliance on third parties for manufacturing and related technical operations.

In practical terms, the supply chain includes:

• sourcing active pharmaceutical ingredient and excipients;
• contract manufacturing of finished topical products;
• quality assurance, testing, and release processes;
• packaging and labeling;
• inventory management and demand planning;
• distribution into wholesale, pharmacy, and patient-access channels.

Supply-chain reliability matters strategically because dermatology launches can be hurt by stock-outs, slow replenishment, or poor coordination between demand generation and pharmacy availability. The supply chain also affects working capital: branded launches often require inventory build and careful planning around returns, channel stocking, and gross-to-net assumptions. For Arcutis, the challenge is less manufacturing complexity than coordination complexity across external partners.

17. What Are the Key Assets of Arcutis?

Arcutis is not especially asset-heavy in the sense of owning large plants, fleets, or mineral reserves. Its critical assets are mostly intangible and regulatory.

• Intellectual property. Patents and know-how around roflumilast formulations and dermatology applications are foundational assets.
• Regulatory approvals. Approved labels for Zoryve are high-value assets because they create legal and commercial access to the market.
• Clinical data package. Trial results that support safety, efficacy, and tolerability are essential competitive assets in physician-facing markets.
• Commercial dermatology infrastructure. The sales, market access, and medical affairs platform is an important asset because it can be leveraged across additional indications.
• Cash and financial flexibility. For a commercial-stage biotech, liquidity is a strategic asset because it determines how aggressively the company can invest behind launches and lifecycle development.

This asset profile affects returns. Arcutis has relatively low fixed-asset intensity but high dependence on successful R&D, regulatory execution, and commercialization. That creates operating leverage if prescriptions scale, but it also means setbacks in approval or market access can have an outsized effect.

18. What Is the R&D Strategy of Arcutis?

R&D is central to Arcutis’s strategy. The company’s approach has not been to pursue the broadest possible pipeline, but to invest deeply in dermatology programs where formulation quality, clinical endpoint design, and regulatory execution can create meaningful differentiation.

The most important feature of Arcutis’s R&D strategy is franchise expansion around topical roflumilast. That means:

• developing different vehicles suited to different disease presentations;
• pursuing additional indications in large inflammatory skin conditions;
• seeking label expansion into broader patient populations where data justify it;
• using clinical evidence to support both regulatory approvals and commercial positioning.

This strategy is efficient if it works. One molecule can support multiple commercial opportunities, physician familiarity can compound over time, and development risk may be lower than starting from scratch with a totally unrelated asset. The trade-off is concentration risk: Arcutis’s R&D value creation as of 2024 was heavily tied to continued success of the roflumilast platform.

19. What Is the Finance Strategy of Arcutis?

Arcutis’s finance strategy is typical of a commercial-stage biotech transitioning from development to revenue growth. The central financial question is not dividend policy or balance-sheet optimization for a mature company; it is how to fund commercialization and label expansion without losing strategic flexibility.

Key elements include:

• Preserve liquidity. Cash is strategically important because launch spending, R&D, and working capital needs can all rise before profitability is achieved.
• Prioritize high-return spending. Capital allocation needs to favor programs and commercial actions with the clearest path to prescription growth or label expansion.
• Manage operating burn. Gross margin on branded topicals can be attractive, but SG&A and R&D can keep the company loss-making until revenue reaches greater scale.
• Maintain financing flexibility. Like many biotech companies, Arcutis has historically depended more on external capital and market access than on internally generated cash flow.
• Improve gross-to-net quality. In branded pharma, net revenue realization can matter nearly as much as prescription volume, so payer contracting and affordability design are financial as well as commercial decisions.

In strategic terms, finance supports the broader corporate plan by deciding how fast Arcutis can build the Zoryve franchise and how many adjacent opportunities it can pursue at once.

20. How Companies Like Arcutis Leverage Independent Consultants through Umbrex

Companies like Arcutis often face a specific management challenge: they need top-tier strategic and operational talent, but they do not always need a full consulting team with the overhead of a major firm. Umbrex has built a global community of more than 8,000 independent management consultants across more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. For a focused dermatology company such as Arcutis, that model can be especially useful during periods of launch execution, indication expansion, payer negotiation, supply-chain scaling, and commercial operating-model refinement.

• Zoryve franchise strategy refresh. Reassess where Arcutis should concentrate investment across psoriasis, seborrheic dermatitis, atopic dermatitis, and future lifecycle extensions.
• Launch readiness for a new indication. Build an integrated plan covering forecasting, demand scenarios, payer strategy, sales messaging, and post-approval execution.
• Payer access and gross-to-net optimization. Diagnose formulary gaps, rebate economics, prior-authorization friction, and patient-affordability design.
• Dermatology sales-force sizing and territory design. Rework targeting, call plans, account prioritization, and sales coverage as the franchise broadens.
• Specialty pharmacy and patient-support redesign. Improve prescription conversion, reduce abandonment, and streamline refill and adherence workflows.
• Commercial analytics dashboard build. Create management dashboards linking physician targeting, payer access, filled scripts, refill rates, and gross-to-net performance.
• Supply-chain risk assessment. Review CMO concentration, inventory policy, launch stocking assumptions, and contingency planning for a growing branded franchise.
• Ex-U.S. partnering strategy. Screen target markets, prioritize licensing structures, and develop partner-selection criteria for selective international expansion.
• R&D portfolio prioritization. Evaluate which lifecycle programs or adjacent dermatology assets deserve capital based on probability-adjusted value and strategic fit.
• Commercial-stage operating model and cost discipline. Identify where Arcutis can add scale efficiently while protecting cash runway and preserving flexibility.